Knowles to Participate in Upcoming Conferences

ITASCA, Ill.--(BUSINESS WIRE)-- Knowles Corporation (NYSE: KN), a leading manufacturer of specialty electronic components, including high performance capacitors, radio frequency ("RF") filters, advanced medtech microphones, and balanced armature speakers, today announced it will participate in an upcoming conferences.

John Anderson, CFO of Knowles will participate in the 2nd Annual Spring One-on-One Virtual Conference Wednesday, May 13th, 2026. Contact your CJS Securities representative to schedule a meeting with management.

John Anderson, CFO of Knowles will participate in The J.P. Morgan Global Technology, Media and Communications Conference in Boston on May 18th and 19th, 2026. Knowles Corporation is scheduled to present at the conference on Monday, May 18th at 4:10pm EST. Contact your J.P. Morgan representative to schedule a meeting with management.

About Knowles

Knowles is a leading manufacturer of specialty electronic components. We design parts that perform unique, critical functions for innovative technologies. Through extreme reliability, custom engineering, and scalable manufacturing, we enable businesses to succeed in the most demanding applications across Medtech, Defense, and Industrial markets.

Our high-performance capacitors, RF and microwave filters, advanced medtech microphones, balanced armature speakers, and miniaturization products enable and enhance the performance of technologies with the power to change, improve, and save lives. Founded in 1946 and headquartered in Itasca, Illinois, Knowles has grown into a global organization with employees spanning 11 countries.

For more information, please visit knowles.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260413415620/en/

Financial Contact:
Sarah Cook
Knowles Investor Relations
Email: [email protected]

Source: Knowles Corporation

You May Also Be Interested In

• Time for Doug Ford to face reality: CUPE Ontario
• LICT Corporation Reports First Quarter 2026 Results
• FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance